论文部分内容阅读
目的探讨西格列汀二甲双胍片治疗新发2型糖尿病(T2DM)的临床疗效和安全性。方法以2014年8月至2016年8月期间住院治疗的120例新发T2DM患者为研究对象,随机分为观察组(60例)和对照组(60例)。其中对照组口服二甲双胍,观察组口服西格列汀二甲双胍片(捷诺达)。在治疗开始和疗程结束后分别检测患者空腹血糖(FPG)、餐后2 h血糖(2hPG)及糖化血红蛋白(HbA_(1c))水平,观察并记录治疗期间的各种不良反应。结果观察组FPG、2hPG以及HbA_(1c)三项指标治疗后下降值均多于对照组,差异有统计学意义(P<0.05);观察组不良反应发生率(5.00%)低于对照组(18.33%),差异有统计学意义(P<0.05)。结论西格列汀二甲双胍片治疗新发T2DM疗效显著,不良反应发生率较低。
Objective To investigate the clinical efficacy and safety of sitagliptin metformin tablet in the treatment of newly diagnosed type 2 diabetes mellitus (T2DM). Methods A total of 120 newly diagnosed T2DM patients admitted to hospital from August 2014 to August 2016 were randomly divided into observation group (60 cases) and control group (60 cases). The control group was given metformin orally and the observation group was given sitagliptin metformin tablet (Jie Nuoda). Fasting blood glucose (FPG), 2h postprandial glucose (2hPG) and glycosylated hemoglobin (HbA_ (1c)) levels were measured at the beginning of treatment and after treatment, and various adverse reactions during treatment were observed and recorded. Results The decrease of FPG, 2hPG and HbA_ (1c) in the observation group were more than those in the control group (P <0.05). The incidence of adverse reactions in the observation group (5.00%) was lower than that in the control group 18.33%), the difference was statistically significant (P <0.05). Conclusion Sitagliptin metformin tablets have a significant effect in the treatment of newly diagnosed T2DM patients with a low incidence of adverse reactions.